12278 Scripps Summit Drive
San Diego, CA 92131
858 875 1800
Full-time employees: 551
|Mr. J. Scott Wolchko||Founder, CEO, Pres & Director||976k||25.12M||1970|
|Mr. Edward J. Dulac III||Chief Financial Officer||588k||821.37k||1976|
|Ms. Cindy R. Tahl||Gen. Counsel & Corp. Sec.||602k||13.37M||1973|
|Dr. Bahram Valamehr Ph.D.||Chief R&D Officer||602k||7.11M||1977|
|Dr. Yu-Waye Chu M.D.||Chief Medical Officer||602k||263.51k||N/A|
|Mr. Jim Beitel M.B.A.||Sr. VP of Corp. Devel.||N/A||N/A||N/A|
|Dr. Sarah Cooley||Sr. VP of Clinical Translation||N/A||N/A||N/A|
|Dr. Jerome Bressi Ph.D.||Sr. VP of Regulatory & Quality||N/A||N/A||N/A|
|Mr. Brian T. Powl M.B.A., M.S.||Chief Commercial Officer||N/A||N/A||N/A|
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma and FT522, to treat lymphoma and autoimmune disorders; and CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Fate Therapeutics, Inc.’s ISS governance QualityScore as of 1 March 2023 is 7. The pillar scores are Audit: 7; Board: 6; Shareholder rights: 8; Compensation: 8.